U.S. Stock Movement: Kodiak Sciences plunges on October 5 due to post-surge correction, financing dilution, and approval uncertainty

Interpretation of Kodiak Sciences' Sharp Drop on October 5

Keywords: Sharp rally and pullback, financing dilution, approval uncertainty

1. On September 28, 2026, the company announced that its DAYBREAK Phase III trial achieved dual primary endpoints, leading the stock price to surge by 177.96% that day. As of October 5, the cumulative gain for the year was 214.11%. After a rapid short-term revaluation, there is pressure from profit-taking and a pullback at high levels, with a 2.33% cumulative decline over the past five days.

2. As of September 30, 2026, the company was still in the pre-commercialization stage, with quarterly cash burn exceeding $60 million and cash on hand of approximately $126 million. Potential follow-up equity financing could bring dilution pressure for shareholders.

3. On September 28, 2026, although the company announced key trial results met the endpoints, Zenkuda still needs to submit a Biologics License Application and obtain regulatory approval. The commercialization prospects, pricing, and competitive landscape remain unclear.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)